Vanessa Broadhurst currently serves as the Executive Vice President, Global Corporate Affairs, at Johnson & Johnson, a global company focused on products related to human health and well-being, where she is also a member of the company’s Executive Committee. At Johnson & Johnson, Ms. Broadhurst leads the company’s corporate marketing, global communications, Health & Wellness Solutions, global public health and philanthropy functions. In this role, Ms. Broadhurst’s responsibilities include leading human capital management for a significant number of employees. Previous to the consumer separation of Kenvue from Johnson & Johnson in 2023, she additionally led consumer communications, design, including packaging, and product design.

Prior to her current role at Johnson & Johnson, Ms. Broadhurst served as Company Group Chairman, Global Commercial Strategy for Pharmaceuticals from 2019 to December 2021 and President, Cardiovascular and Metabolism from 2017 to 2018. Prior to Johnson & Johnson, Ms. Broadhurst was General Manager, Cardiovascular and Bone Business Units at Amgen (2014 – 2017), in these roles she had a leadership position in M&A activity, pipeline development and new product launch strategy. Previously she served as General Manager, Inflammation and Cardiovascular Business Units at Amgen (2013 – 2014). From 2005 to 2013 Ms. Broadhurst served in various senior leadership roles at Johnson & Johnson. Prior to 2005 Ms. Broadhurst was Head, Global Gastroenterology Marketing at Novartis (2003 – 2005) and served in various roles of increasing responsibility at Abbott Laboratories (1994 – 2003).

Ms. Broadhurst serves as a member of The Executive Leadership Council (ELC) and as a Board member of the Ad Council. She received a Master of Business Administration from the Ross School of Business at the University of Michigan, where she was a Consortium Fellow, and a Bachelor of Arts degree from the University of Colorado, Boulder. Ms. Broadhurst’s consumer healthcare marketing and digital communications expertise, as well as her business experience with the global pharmaceutical industry, make her a valuable member of our Board.